Analysis of Epirubicin in Treating Non-muscle Invasive Bladder Tumors: Retrospective Descriptive Analysis, Monocentric Study

Résumé fourni par la source

Purpose: BCG and MMC are the most popular drugs for adjuvant intravesical instillations in Non-Muscle-Invasive Bladder Cancer (NMIBC). In recent years, there has been a risk of shortage of these two agents worldwide. For this reason, our study aims to determine the characteristics of NMIBC in our department and the results following their treatment with Epirubicin. Methods: This inquiry is a retrospective descriptive study of 09 patients regrouped from the Urology Department of Cheikh Khalifa Hospital. Results: The results obtained revealed a predominance of low-grade urothelial carcinomas with an intermediate risk of recurrence and progression. Intravesical instillations of Epirubicin have shown a recurrence rate of 44.44% and a progression rate of 33.33%, with local side effects observed in 5 patients. Conclusion: Despite the limited number of patients in our study, treatment with Epirubicin has demonstrated therapeutic efficacity, approaching that of BCG and MMC, with an acceptable toxic profile.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.